Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00764465 · ClinicalTrials.gov registry record · Phase 2
An Interaction Study to Assess Drug Levels in Healthy Adult Subjects
A Phase 2 study of Healthy, sponsored by Garden State Infectious Disease Associates, PA.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT00764465: Completed Phase 2 study of Healthy, sponsored by Garden State Infectious Disease Associates, PA.
NCT00764465 is a Phase 2 study of Healthy that has completed, run by Garden State Infectious Disease Associates, PA. The registered enrollment target is 45 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00764465, a Phase 2 study of Healthy, has completed, sponsored by Garden State Infectious Disease Associates, PA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
To date, no study has investigated whether there is a drug interaction between the protease inhibitor fosamprenavir and the entry inhibitor maraviroc. COL112237 is a randomized, open-label, 6-arm, 3-period, drug interaction study to assess steady-state plasma amprenavir (APV) and maraviroc (MVC) pharmacokinetics in 48 healthy, HIV-negative adults after administration of a 7-day regimen of MVC 300mg BID alone and after 14-day regimens of unboosted fosamprenavir (FPV) 1400mg twice daily (BID), FPV 700mg/RTV 100mg BID, or FPV 1400mg/ritonavir (RTV) 100mg once daily (QD) with and without concurrent MVC 300mg BID. Blood samples for drug concentration measurement will be collected over 12 hours at the end of each dosing period. Subjects will undergo a physical examination, complete blood count (CBC) with differential, HIV test, hepatitis B/C test, liver function test, renal function analysis, and lipid panel at screening, and all of these tests, except those for HIV and hepatitis B/C, will be repeated at follow-up post-study. Adverse events and adherence (by pill count and medication diary) will be assessed by the investigator/study personnel at the end of each dosing period.
Primary Outcome
Amprenavir (APV) is the active ingredient/metabolite of Fosamprenavir (FPV).
Conditions Studied
Interventions
- DRUG Ritonavir
- DRUG Maraviroc
- DRUG Fosamprenavir
Study Locations (1)
New Jersey
- Garden State Infectious Disease Associates,PA - Voorhees Township
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-10 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
What the finished NCT00764465 record still lists
NCT00764465 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Ritonavir is the first listed.
NCT00764465 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00764465 about?
NCT00764465 is a clinical study titled "An Interaction Study to Assess Drug Levels in Healthy Adult Subjects". To date, no study has investigated whether there is a drug interaction between the protease inhibitor fosamprenavir and the entry inhibitor maraviroc. COL112237 is a randomized, open-label, 6-arm, 3-period, drug interaction study to assess steady-state plasma amprenavir (APV) and maraviroc (MVC) pha...
What is the current status of trial NCT00764465?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2008-10. Estimated completion is 2008-12.
What conditions does trial NCT00764465 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT00764465?
The interventions under investigation include: Ritonavir (DRUG), Maraviroc (DRUG), Fosamprenavir (DRUG).
Who is sponsoring clinical trial NCT00764465?
This trial is sponsored by Garden State Infectious Disease Associates, PA, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00764465 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00764465's enrollment target sits among peer trials
45 500th of 1090 higher than 586 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Effects of an Antioxidant Supplement on Blood Vessel Health
RECRUITING · Phase 2
-
Atenolol for the Prevention of Osteoporosis (APO)
ACTIVE NOT RECRUITING · Phase 2
-
Effectiveness of Aquamin® in Mitigating Halitosis
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia